|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 4500 East West Highway |
Address2 | Suite 900 |
City | BETHESDA |
State | MD |
Zip Code | 20814 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 3457-12
|
||||||||
|
6. House ID# 315500000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Thomas Kraus |
Date | 7/20/2023 3:10:30 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to drug pricing, drug shortages, and the drug supply chain, including support for the following bills: the Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), the Pharmacy Benefits Manager Accountability Act (H.R. 2679), and the Promoting Transparency and Healthy Competition in Medicare Act (H.R. 3282).
Issues related to COVID-19 response and post-public health emergency recommendations, including telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation).
Issues related to combatting opioid addiction (generally, no specific legislation).
Patient access to pharmacist provided vaccinations for COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, initiation of oral antivirals for flu/COVID, Buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation).
Reauthorization of the Pandemic and All-Hazards Preparedness Act, including recommendations to leverage pharmacists as part of the care team.
Patient access to comprehensive reproductive healthcare (generally, no specific legislation).
Issues related to healthcare workforce shortages (generally, no specific legislation).
Issues related to site neutral payments (generally, no specific legislation).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jillanne |
Schulte |
|
|
|
Thomas |
Kraus |
|
|
|
Frank |
Kolb |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
The Equitable Community Access to Pharmacist Services Act (H.R. 1770) and the Pharmacy and Medically Underserved Areas Enhancement Act (S. 1491), provisions related to Medicare coverage for all PREP Act services and COVID-19 response recommendations, including Medicaid reimbursement for pharmacist provision of testing and vaccination.
Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation).
Issues related to continuation of Public Readiness and Emergency Preparedness Act (PREP Act) allowances (generally, no specific legislation).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jillanne |
Schulte |
|
|
|
Thomas |
Kraus |
|
|
|
Frank |
Kolb |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act.
The PROTECT 340B Act (H.R. 2534), provisions related to enforcement of the 340B Drug Pricing Program.
Issues related to pharmacy residency funding (generally, no specific legislation).
Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jillanne |
Schulte |
|
|
|
Thomas |
Kraus |
|
|
|
Frank |
Kolb |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |